The company's strong revenue growth for Briumvi was overshadowed by an EPS miss, primarily due to higher non-cash compensation and R&D investments. The deceleration in revenue growth and competitive pressures from Ocrevus and Kesimpta likely contributed to the negative market reaction, despite the raised full-year revenue guidance.